MabThera + Physiological serum : sodium chloride, sodium citrate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Humoral Rejection in Kidney Transplantation
Conditions
Humoral Rejection in Kidney Transplantation
Trial Timeline
Oct 1, 2008 → Oct 1, 2012
NCT ID
NCT01350882About MabThera + Physiological serum : sodium chloride, sodium citrate
MabThera + Physiological serum : sodium chloride, sodium citrate is a phase 3 stage product being developed by Roche for Humoral Rejection in Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01350882. Target conditions include Humoral Rejection in Kidney Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01350882 | Phase 3 | Completed |
Competing Products
1 competing product in Humoral Rejection in Kidney Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bivigam | ADMA Biologics | Approved | 80 |